4 Einträge gefunden

1. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

   1. Mai, Elias K
   2. Miah, Kaya
   3. Bertsch, Uta
   4. Dürig, Jan
   5. Scheid, Christof
   6. Weisel, Katja C
   7. Kunz, Christina

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Response-adapted lenalidomide maintenance in newly diagnosed myeloma:results from the phase III GMMG-MM5 trial

   1. Goldschmidt, Hartmut
   2. Mai, Elias K
   3. Dürig, Jan
   4. Scheid, Christof
   5. Weisel, Katja C
   6. Kunz, Christina
   7. Bertsch, Uta

   2020 - Forschungsinformationssystem des UKE
3. Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

   1. Weisel, Katja C
   2. Scheid, Christof
   3. Zago, Manola
   4. Besemer, Britta
   5. Mai, Elias K
   6. Haenel, Mathias
   7. Duerig, Jan

   2019 - Forschungsinformationssystem des UKE
4. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

   1. Salwender, Hans
   2. Bertsch, Uta
   3. Weisel, Katja
   4. Duerig, Jan
   5. Kunz, Christina
   6. Benner, Axel
   7. Blau, Igor W

   2019 - Forschungsinformationssystem des UKE - frei zugänglich